B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

BCL2L1

MOLECULAR TARGET

BCL2 like 1

UniProt: CAA80661NCBI Gene: 59810 compounds

BCL2L1 (BCL2 like 1) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting BCL2L1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1paxilline1.102
2Tannins Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS).0.691
3Anthralin0.691
4Aurintricarboxylic Acid0.691
5Domperidone0.691
6Metergoline0.691
7Masoprocol0.691
8Oxytetracycline0.691
9Tetracycline0.691
10vinblastine sulfate0.691

About BCL2L1 as a Drug Target

BCL2L1 (BCL2 like 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented BCL2L1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

BCL2L1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.